Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. covers the month of July 2012, specifically dated July 25, 2012. The report details an amendment to a funding agreement previously entered into on December 20, 2011, with Baize Investments (Israel) Ltd. ("Baize"). The agreement involves research funding for the development of therapeutic monoclonal antibody (mAb) product candidates in the field of oncology.
Key Financial Metrics
The filing does not provide standard financial statements such as revenue, profit, cash flow, or margins. The primary financial data relates to the funding agreement:
- Total Investment Amount: $8,000,000.
- Initial Payment: $2,000,000 (paid within five business days of the December 2011 agreement).
- Remaining Investment Amount: $6,000,000 (subject to the July 2012 amendment).
- Contingent Conversion Price: $6.00 per share (if remaining payments are not made).
Material Changes Versus Prior Period
On July 24, 2012, Compugen and Baize executed an amendment to the original funding agreement with the following material changes:
- Scope Reduction: The number of specified oncology targets for mAb development was reduced from 12 to eight.
- Payment Schedule Adjustment: The payment dates for the remaining $6,000,000 were revised:
- $1,000,000 is now due on or before July 31, 2012.
- $5,000,000 is now due on or before December 31, 2012.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Terms: Baize is entitled to a "Participation Interest" if an mAb candidate achieves a successful animal disease model or is licensed out within three years. This interest grants Baize a percentage of future payments from third-party out-licensing, calculated on a sliding scale based on funding contributions, with a guaranteed minimum of 10%.
Risks and Contingencies: If the remaining investment amount is not paid according to the amended schedule, Compugen has the right to exchange the Participation Interest for Ordinary Shares. The number of shares would be calculated by dividing the Investment Amount paid to date by $6.00 per share. Upon such an exchange, all future financial interests for Baize would be terminated.
Key Facts for Investor Verification
- Verify the receipt of the $1,000,000 installment due by July 31, 2012.
- Confirm the status of the $5,000,000 installment due by December 31, 2012.
- Monitor whether the reduction from 12 to 8 targets impacts the company's overall R&D pipeline strategy.
- Assess the risk of the Participation Interest converting to equity at $6.00 per share if funding milestones are missed.